8-K: Indaptus Therapeutics Secures $2.3 Million in Initial Private Placement to Advance Clinical Trials

Indaptus Therapeutics, a clinical-stage biotechnology company, has announced the initial closing of a private placement, raising $2.3 million through the sale of convertible notes and warrants, with proceeds earmarked for research and development, including a Phase 1b/2 clinical trial.

Summary

• Indaptus Therapeutics, Inc. (INDP) completed an initial closing of a private placement on June 12, 2025, raising $2.3 million in gross proceeds.
• The private placement involved the sale of convertible promissory notes and warrants to accredited investors.
• The notes bear an interest rate of 6% per year and will mature on July 28, 2026.
• Notes will mandatorily convert into common stock on the earlier of 30 days from a Nasdaq reverse split effectiveness or the one-year anniversary of issuance.
• The conversion price for the notes is 80% of the 5-day average Nasdaq official closing price preceding the conversion date, capped at $0.40 per share.
• Warrants will be issued to purchasers, exercisable for shares equal to 200% of conversion shares if subscribed by June 30, 2025, or 100% if subscribed thereafter.
• The warrants have an exercise price equal to the conversion price and expire five years from their issuance date.
• Paulson Investment Company, LLC acted as the exclusive placement agent, receiving a 12% cash commission on gross proceeds (excluding sales to company directors/executive officers) and a $25,000 non-accountable expense fee.
• Paulson Investment Company, LLC also received placement agent warrants exercisable for 12% of the total common stock sold in the offering, with cashless exercise provisions and a 5-year term.
• The company intends to use the net proceeds for research and development activities, including funding a Phase 1b/2 clinical trial, as well as for working capital and general corporate purposes.
• The offering is ongoing, with the company seeking to raise up to a maximum of $5 million in gross proceeds on the same terms, unless increased at the company's discretion.
• The company has agreed to file a registration statement within 30 days of the Conversion Date for the resale of the conversion shares and warrant shares, aiming for effectiveness within 60 days (or 90 days if SEC review) and to keep it effective for two years or until no purchaser owns the securities.
• The issuance of shares upon conversion is subject to Nasdaq Listing Rule 5635(d) (19.99% cap), which will not apply if stockholder approval is obtained; the company has agreed to seek this approval.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the capital raise provides essential funding for clinical development, the terms (e.g., high placement agent fees, potential dilution from warrants and discounted conversion price) reflect the challenges and costs associated with financing a clinical-stage biotech company. The ongoing nature of the raise and the need for shareholder approval for full conversion also introduce some uncertainty.

Positives

• Successfully secured $2.3 million in initial gross proceeds, providing capital for operations and clinical development.
• The funding is specifically allocated to support research and development, including a crucial Phase 1b/2 clinical trial, which is vital for a clinical-stage biotechnology company.
• The ongoing nature of the offering allows for potential additional capital raises up to $5 million, providing flexibility for future funding needs.
• The engagement of an exclusive placement agent, Paulson Investment Company, LLC, indicates a structured approach to capital raising.

Negatives

• The conversion price for the notes is set at 80% of the 5-day average Nasdaq closing price, subject to a maximum of $0.40, which could lead to significant dilution for existing shareholders if the stock price is higher.
• The issuance of warrants, particularly at 200% of conversion shares for early subscribers, represents substantial potential future dilution.
• The company's ability to issue shares beyond the Nasdaq 19.99% cap is contingent on obtaining stockholder approval, which introduces a potential hurdle.
• The company's financial condition and ability to continue as a going concern are highlighted as risks in the forward-looking statements, indicating ongoing financial challenges.

Risks

• Limited operating history and substantial doubt regarding the company's ability to continue as a going concern.
• Ongoing need for, and ability to raise, additional capital due to lack of current cash flow.
• Clinical and preclinical development processes are lengthy, expensive, and have uncertain outcomes.
• Incurrence of significant research and development and other operating expenses, making profitability difficult to attain.
• Reliance on a limited number of research programs, product candidates, and specific indications, with the risk of missing more profitable opportunities.
• Challenges in obtaining and maintaining regulatory approval for any product candidates.
• Uncertainty regarding market acceptance of product candidates.
• Reliance on third parties to conduct preclinical studies, clinical trials, and manufacturing.
• Ability to successfully commercialize Decoy20 or any future product candidates is not guaranteed.
• Challenges in obtaining or maintaining coverage and adequate reimbursement for products.
• Impact of legislation and healthcare reform measures on marketing approval and commercialization.
• Competitor products may be approved faster, marketed more effectively, or be better tolerated.
• Difficulty in adequately protecting proprietary or licensed technology.
• Information technology system failures, cyberattacks, or cybersecurity deficiencies.
• Unfavorable global economic conditions could adversely affect the company's operations and financial health.

Future Outlook

Indaptus Therapeutics intends to use the net proceeds from the offering primarily for research and development activities, specifically funding a Phase 1b/2 clinical trial, alongside general working capital and corporate purposes. The company plans to continue the offering to raise up to a maximum of $5 million. A registration statement for the resale of conversion and warrant shares will be filed within 30 days of the Conversion Date, with efforts to make it effective within 60-90 days and maintain effectiveness for two years.

Management Comments

• Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced the sale of approximately $2.3 million in aggregate principal amount of convertible promissory notes and accompanying warrants.

Industry Context

This private placement by Indaptus Therapeutics is consistent with capital raising strategies often employed by clinical-stage biotechnology companies. Such companies typically rely on external funding to finance extensive and costly research and development activities, particularly clinical trials, given their limited or non-existent revenue streams. The use of convertible notes and warrants is a common structure in the biotech sector to attract institutional investors, offering potential upside through equity conversion while providing debt-like security. The focus on cancer and viral infection treatments aligns with significant and ongoing investment interest in these therapeutic areas.

Comparison to Industry Standards

• The 6% interest rate on convertible notes is within a reasonable range for a clinical-stage biotech company, reflecting a balance between investor return and company cost of capital, though specific comparables would depend on the company's stage, pipeline, and market conditions.
• The 12% cash commission and 12% warrant coverage for the placement agent are on the higher end of typical fees for private placements in the biotech sector, which can range from 5% to 10% cash and 5% to 10% warrant coverage, reflecting the perceived risk and effort involved in raising capital for a clinical-stage company.
• The conversion price at 80% of VWAP with a $0.40 cap is a common structure in such financings, designed to provide investors with a discount to market price while setting a floor, but the specific cap of $0.40 would need to be assessed against the company's current trading price and historical volatility for a more precise comparison.
• The beneficial ownership limitations (4.99%/9.99%) and the Nasdaq 19.99% cap are standard provisions to ensure compliance with exchange rules and prevent immediate change of control without shareholder approval, aligning with corporate governance best practices for publicly traded companies.

Corporate Governance

Stakeholder Impact

• **Shareholders**: Potential dilution from the conversion of notes and exercise of warrants, especially if the stock price is above the $0.40 cap. However, the capital raise funds critical R&D, which could lead to long-term value creation if clinical trials are successful.
• **Investors (Purchasers)**: Gain exposure to the company's potential upside through convertible notes and warrants, with a discounted conversion price and significant warrant coverage, providing a favorable entry point.
• **Employees**: Continued funding for R&D activities supports ongoing operations and job security, particularly for those involved in the Phase 1b/2 clinical trial.
• **Creditors**: The convertible notes represent a new financial obligation, but the proceeds are intended for R&D and working capital, which could strengthen the company's overall financial position if successful.

Next Steps

• Continue the private placement offering to raise additional gross proceeds up to the $5 million maximum (or higher if discretionarily increased).
• File a registration statement on Form S-3 within 30 days of the Conversion Date for the resale of Conversion Shares and Common Warrant Shares.
• Use commercially reasonable efforts to cause the registration statement to become effective within 60 days (or 90 days if SEC review) following the Conversion Date.
• Maintain the effectiveness of the registration statement for two years or until no Purchaser owns the registered securities.
• Hold a special stockholder meeting to seek stockholder approval for the issuance of Conversion Shares and Warrant Shares in excess of the Nasdaq 19.99% cap, if required.

Key Dates

Recommendation

Keywords

Biotechnology, Cancer treatment, Viral infection treatment, Clinical stage, Private placement, Convertible notes, Warrants, Capital raise, SEC filing, INDP, Nasdaq, Phase 1b/2 clinical trial, Dilution, Accredited investors